This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.
This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.
Given that 9 out of 10 people with diabetes also suffer from overweight or obesity, it is important for PCPs to take a holistic approach to treatment rather than solely a glucocentric approach. This activity helps you understand the benefits of weight loss as a key therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM) and the importance of early treatment intensification to improve long-term outcomes. You’ll also walk away from this session with a firm grasp of the role incretins play in the pathophysiology of T2DM, obesity, and other metabolic conditions and the latest clinical trial evidence behind incretin-based agents.